Zevra Therapeutics Inc
ZVRA8.870USD
+0.230+2.66%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
498.65MMarket Cap
14.70P/E TTM
More Details of Zevra Therapeutics Inc Company
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
Zevra Therapeutics Inc Info
Ticker SymbolZVRA
Company nameZevra Therapeutics Inc
IPO dateApr 16, 2015
CEOMcfarlane (Neil F)
Number of employees59
Security typeOrdinary Share
Fiscal year-endApr 16
Address1180 Celebration Boulevard
CityCELEBRATION
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code34747
Phone13219393416
Websitehttps://zevra.com/
Ticker SymbolZVRA
IPO dateApr 16, 2015
CEOMcfarlane (Neil F)
Company Executives of Zevra Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
222.02K
+15.93%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
45.00K
+12.50%
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Alvin Shih, M.D.
Dr. Alvin Shih, M.D.
Independent Director
Independent Director
--
--
Dr. Adrian Quartel, M.D.
Dr. Adrian Quartel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Corey Watton
Mr. Corey Watton
Independent Director
Independent Director
--
--
Mr. Rahsaan W. Thompson
Mr. Rahsaan W. Thompson
Chief Legal Officer, Secretary, Compliance Officer
Chief Legal Officer, Secretary, Compliance Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
222.02K
+15.93%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
45.00K
+12.50%
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Alvin Shih, M.D.
Dr. Alvin Shih, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2024
FY2023
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
25.88M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.53%
Woodline Partners LP
6.17%
The Vanguard Group, Inc.
5.48%
Adage Capital Management, L.P.
3.95%
Nantahala Capital Management, LLC
3.50%
Other
74.37%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.53%
Woodline Partners LP
6.17%
The Vanguard Group, Inc.
5.48%
Adage Capital Management, L.P.
3.95%
Nantahala Capital Management, LLC
3.50%
Other
74.37%
Shareholder Types
Shareholders
Proportion
Hedge Fund
24.62%
Investment Advisor
24.56%
Investment Advisor/Hedge Fund
16.60%
Research Firm
3.61%
Private Equity
1.62%
Individual Investor
0.80%
Venture Capital
0.33%
Bank and Trust
0.16%
Pension Fund
0.14%
Other
27.57%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
256
37.37M
66.37%
-1.07M
2025Q2
239
33.85M
61.90%
-4.28M
2025Q1
252
39.54M
72.42%
-1.74M
2024Q4
247
37.53M
70.32%
+3.07M
2024Q3
232
32.67M
61.46%
+11.34M
2024Q2
214
19.77M
45.38%
+395.88K
2024Q1
213
17.66M
40.45%
-265.50K
2023Q4
207
16.32M
37.86%
+175.17K
2023Q3
203
14.77M
38.14%
-620.11K
2023Q2
208
12.57M
36.97%
-1.13M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
3.72M
6.62%
-68.78K
-1.82%
Jun 30, 2025
Woodline Partners LP
4.62M
8.22%
+51.00
+0.00%
Jun 30, 2025
The Vanguard Group, Inc.
2.95M
5.26%
+126.84K
+4.49%
Jun 30, 2025
Adage Capital Management, L.P.
4.17M
7.42%
+550.00K
+15.20%
Jun 30, 2025
Nantahala Capital Management, LLC
1.47M
2.62%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
2.20M
3.92%
+10.59K
+0.48%
Jun 30, 2025
State Street Investment Management (US)
1.24M
2.21%
+65.11K
+5.53%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.24M
2.21%
+9.28K
+0.75%
Jun 30, 2025
Legal & General Investment Management Ltd.
935.68K
1.67%
+197.94K
+26.83%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Propel Opportunities ETF
2.21%
State Street SPDR S&P Pharmaceuticals ETF
1.46%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.04%
Federated Hermes MDT Small Cap Core ETF
0.19%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.05%
Vanguard US Momentum Factor ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
View more
Simplify Propel Opportunities ETF
Proportion2.21%
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.46%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.04%
Federated Hermes MDT Small Cap Core ETF
Proportion0.19%
iShares Micro-Cap ETF
Proportion0.11%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.05%
Vanguard US Momentum Factor ETF
Proportion0.05%
iShares Russell 2000 Growth ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Zevra Therapeutics Inc?
The top five shareholders of Zevra Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A. holds 3.72M shares, accounting for 6.62% of the total shares.
Woodline Partners LP holds 4.62M shares, accounting for 8.22% of the total shares.
The Vanguard Group, Inc. holds 2.95M shares, accounting for 5.26% of the total shares.
Adage Capital Management, L.P. holds 4.17M shares, accounting for 7.42% of the total shares.
Nantahala Capital Management, LLC holds 1.47M shares, accounting for 2.62% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.72M shares, accounting for 6.62% of the total shares.
Woodline Partners LP holds 4.62M shares, accounting for 8.22% of the total shares.
The Vanguard Group, Inc. holds 2.95M shares, accounting for 5.26% of the total shares.
Adage Capital Management, L.P. holds 4.17M shares, accounting for 7.42% of the total shares.
Nantahala Capital Management, LLC holds 1.47M shares, accounting for 2.62% of the total shares.
What are the top three shareholder types of Zevra Therapeutics Inc?
The top three shareholder types of Zevra Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A.
Woodline Partners LP
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Woodline Partners LP
The Vanguard Group, Inc.
How many institutions hold shares of Zevra Therapeutics Inc (ZVRA)?
As of 2025Q3, 256 institutions hold shares of Zevra Therapeutics Inc, with a combined market value of approximately 37.37M, accounting for 66.37% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 4.47%.
What is the biggest source of revenue for Zevra Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Zevra Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
